Is Travere Therapeutics, Inc. (TVTX) a Buy, Sell, or Hold?
Travere Therapeutics, Inc.
NASDAQ:TVTX
$57.06 USD
$0.77 (1.37%)
- Volume
- 890.17K
- Average Volume
- 2.52M
- Market Capitalization
- $5.31B
- P/E Ratio
- -116.45
- Dividend Yield
- 0.00%
- Price Target
- $65.00
- Year High
- $60.10
- Year Low
- $15.03
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.13
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Eric Dube |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | TVTX |
| CUSIP | 89422G107 |
| CIK | 0001438533 |
| Web | https://www.travere.com |
| Phone | 888 969 7879 |
| Currency | USD |
| Employees | 497 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 3.32 |
| Payout Ratio | 0.00 |
| Current Ratio | 3.13 |
| Quick Ratio | 3.08 |
| Cash Ratio | 0.62 |
Sales & Book Value
| Annual Sales | $490.73M |
| Price / Sales | 9.90 |
| Cash Flow | -0.02 |
| Price / Cash Flow | -2939.71 |
| Price / Book | 53.10 |
Price Target and Rating
| Average Stock Price Forecast | $65.00 |
| High Stock Price Forecast | $67.00 |
| Low Stock Price Forecast | $49.00 |
| Forecast Upside/Downside | -12.22% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 18 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.56 |
| Trailing P/E Ratio | -116.45 |
| PEG Ratio | -0.55 |
| P/E Growth | -0.55 |
| Net Income | $-25.55M |
| Net Margin | -4.00% |
| Pretax Margin | -8.36% |
| Return on Equity | -26.79% |
| Return on Assets | -3.86% |
Financials Score
| AltmanZ Score | 4.45 |
| Piotroski Score | 4.00 |
| Working Capital | 267.24M |
| Total Assets | 555.19M |
| Ebit | -34.62M |
| Market Cap | 5.26B |
| Total Liabilities | 456.46M |
Poll Results
About Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopro ... nin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-10 17:00:00
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on July 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 41,600 shares of its common stock to six new employees, consisting of inducement stock options to purchase an aggregate of 18,000 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 23,600 shares of its common stock. These inducement s.
2026-07-08 01:00:00
HONG KONG, July 8, 2026 - (ACN Newswire) - Everest Medicines (HKEX 1952.HK) announced the closing of its previously announced exclusive licensing and collaborat
Travere Therapeutics: Filspari Is Becoming A Rare Kidney Disease Platform
2026-07-03 04:37:04
Travere Therapeutics has transitioned into a rare disease commercial platform, driven by FILSPARI's strong growth in IgAN and recent FSGS approval. TVTX's premium valuation is justified by rapid revenue expansion, significant operating leverage, and strategic pipeline moves like the civorebrutinib acquisition. FILSPARI's unique positioning and first-mover advantage in FSGS, alongside a simplified REMS, support continued market penetration despite a competitive IgAN landscape.
Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027
2026-06-16 16:30:00
SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that William Rote, Ph.D., the Company's chief research officer, plans to retire from the Company in February 2027 following 10 years of service. Jula Inrig, M.D., currently chief medical officer and a member of the Company's executive leadership team, will expand her responsibilities to include the Company's research organization and be named executive vice president, head of research and development and CMO.
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-11 17:00:00
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on June 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 32,000 shares of its common stock. These inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside of the 2018 Plan and were granted as i.
2026-06-08 13:08:31
Travere Therapeutics, Inc. (TVTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
2026-06-04 10:09:00
SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced long-term results from the ongoing Phase 3 DUPLEX Study open-label extension (OLE) of FILSPARI® (sparsentan) in the treatment of focal segmental glomerulosclerosis (FSGS). Patients who initiated FILSPARI in the double-blind period and remained on therapy in the OLE maintained durable reductions in proteinuria, resulting in further achievement of clinically meaningful low proteinuria thresholds over time. Pati.
2026-06-04 00:00:00
HONG KONG, June 4, 2026 - (ACN Newswire) - Everest Medicines (HKEX 1952.HK) announced that it has entered into an exclusive licensing and collaboration agreemen
Frequently Asked Questions
-
What is the current Travere Therapeutics, Inc. (TVTX) stock price?
-
Travere Therapeutics, Inc.(NASDAQ:TVTX) stock price is $57.06 in the last trading session. During the trading session, TVTX stock reached the peak price of $60.1 while $15.03 was the lowest point it dropped to. The percentage change in TVTX stock occurred in the recent session was 1.37% while the dollar amount for the price change in TVTX stock was $0.77.
-
TVTX's industry and sector of operation?
-
The NASDAQ listed TVTX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of TVTX?
-
Jula Inrig | Executive VP, Head of Research & Development and Chief Medical Officer
Sandra Calvin | SVP & Chief Accounting Officer
Eric Dube | President, Chief Executive Officer & Director
William E. Rote | Chief Research Officer
Casey Logan | Chief Business Officer -
How many employees does TVTX have?
-
Number of TVTX employees currently stands at 497. TVTX operates from 3611 Valley Centre Drive, San Diego, CA 92130, US.
-
Link for TVTX official website?
-
Official Website of TVTX is: https://www.travere.com
-
How do I contact TVTX?
-
TVTX could be contacted at phone #888 969 7879 and can also be accessed through its website. TVTX operates from 3611 Valley Centre Drive, San Diego, CA 92130, US.
-
How many shares of TVTX are traded daily?
-
The average number of TVTX shares traded daily for last 3 months was 2.52M.
-
What is the market cap of TVTX currently?
-
The market value of TVTX currently stands at $5.31B with its latest stock price at $57.06